Theravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Theravance Biopharma (TBPH) Misses Q1 EPS by 13c
May 9, 2017 4:44 PM EDTTheravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.27), $0.13 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $5.58 million.
Cash, cash equivalents, and marketable securities totaled $540.7 million as of March 31, 2017.
2017 Financial Guidance
The Company's guidance on operating loss excluding non-cash share-based compensation... More
